Simcere, Bristol-Myers deal

Bristol-Myers granted Simcere exclusive rights in China to develop and commercialize preclinical cardiovascular compound BMS-795311. Bristol-Myers retains rights elsewhere to the small molecule cholesteryl ester transfer protein (CETP) inhibitor. Financial terms were not disclosed. ...